Genentech, Inc.
Also known as: Genentech, Inc.
Organization reference: lei:254900RA7ET1PAV4HP37 · Legal entity
1,645
103
206
1,069
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
17.7%
291 terminated/withdrawn out of 1645 trials
78.6%
-8.0% vs industry average
13%
208 trials in Phase 3/4
68%
728 of 1069 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (1645)
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Role: collaborator
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Role: collaborator
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Role: lead
Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma
Role: collaborator
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Role: lead
A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer
Role: collaborator
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Role: collaborator
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Role: collaborator
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Role: lead
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Role: lead
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Role: collaborator
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
Role: lead
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
Role: collaborator
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Role: lead
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
Role: collaborator
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Role: collaborator
Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
Role: lead
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast Cancer
Role: lead
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Role: collaborator
Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Role: collaborator